IFNA1 and coronary artery disorder: In an open-label, phase 2 trial, NAP REP 2139-Ca was administered as monotherapy to 12 patients with CHD for 15 weeks, followed by 15 weeks of add-on Peg-IFN and then 33 weeks of Peg-IFN monotherapy; overall, 7 patients achieved undetectable HDV-RNA and 4 patients lost HBsAg [59].